Jeil Pharmaceutical Co Ltd Total Liabilities
Jeil Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has total liabilities worth ₩272.85 Billion KRW (≈ $184.91 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Jeil Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jeil Pharmaceutical Co Ltd (2017–2025)
Total liabilities of Jeil Pharmaceutical Co Ltd from 2017 to 2025. This chart illustrates how Jeil Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Jeil Pharmaceutical Co Ltd (271980) investment intensity to see how much of total assets are deployed in long-term investments.
Jeil Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Carlo Gavazzi Holding AG
SW:GAV
|
Switzerland | CHF43.24 Million |
|
Shotspotter Inc
NASDAQ:SSTI
|
USA | $63.58 Million |
|
Tropical Canning (Thailand) Public Company Limited
BK:TC
|
Thailand | ฿1.30 Billion |
|
BingEx Ltd
NASDAQ:FLX
|
USA | $399.94 Million |
|
Enablence Technologies Inc
V:ENA
|
Canada | CA$71.48 Million |
|
Stella Holdings Bhd
KLSE:5006
|
Malaysia | RM768.44 Million |
|
Lotte Himart
KO:071840
|
Korea | ₩967.89 Billion |
|
Brii Biosciences Limited
F:7SS
|
Germany | €36.20 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Jeil Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 271980 total assets.
Liquidity & Leverage Metrics
Jeil Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Jeil Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jeil Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jeil Pharmaceutical Co Ltd (2017–2025)
The table below shows the annual total liabilities of Jeil Pharmaceutical Co Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩259.55 Billion ≈ $175.89 Million |
-15.29% |
| 2024-12-31 | ₩306.38 Billion ≈ $207.63 Million |
-7.24% |
| 2023-12-31 | ₩330.29 Billion ≈ $223.84 Million |
+9.63% |
| 2022-12-31 | ₩301.29 Billion ≈ $204.18 Million |
+16.27% |
| 2021-12-31 | ₩259.14 Billion ≈ $175.61 Million |
+9.26% |
| 2020-12-31 | ₩237.18 Billion ≈ $160.74 Million |
+2.44% |
| 2019-12-31 | ₩231.54 Billion ≈ $156.91 Million |
+6.23% |
| 2018-12-31 | ₩217.97 Billion ≈ $147.71 Million |
-7.54% |
| 2017-12-31 | ₩235.74 Billion ≈ $159.76 Million |
-- |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more